腕戴设备数据用于评估创伤应激暴露后疼痛、睡眠与焦虑结局的效用
本研究基于AURORA研究,分析2021例急诊创伤暴露患者佩戴腕戴设备8周的数据,随机分为等量两半用于生物标志物识别与验证。发现减少的24小时活动变异与更大疼痛严重度相关(r=-0.14;95%CI,-0.20至-0.07),睡眠与清醒间转换次数变化与疼痛、睡眠和焦虑变化相关。简单截断值对疼痛、睡眠和焦虑良好恢复具有较高预测价值。
要点
- 减少的24小时活动变异与更大疼痛严重度相关(r=-0.14;95%CI,-0.20至-0.07)。
- 睡眠与清醒间转换次数变化与疼痛、睡眠和焦虑变化相关。
- 简单截断值预测良好恢复的PPV:疼痛0.85、睡眠0.63、焦虑0.76。
核心结论
- 腕戴设备生物标志物可能作为创伤暴露后疼痛、睡眠和焦虑症状结局的筛查工具。
研究设计与样本
- 数据来自AURORA研究,参与者从27个急诊科招募,在急诊科开始佩戴腕戴设备8周并完成系列神经精神症状评估。
- 数据随机分为两个等量部分(n=1010)用于生物标志物识别和验证。
主要发现
- 在推导队列中,8个腕戴设备生物标志物超过显著性阈值。
- 减少的24小时活动变异与更大疼痛严重度相关(r=-0.14;95%CI,-0.20至-0.07)。
- 6个静息-活动指标的变化与疼痛随时间的变化相关。
- 睡眠与清醒间转换次数的变化与疼痛、睡眠和焦虑的变化相关。
关键数值与推荐
- 简单截断值识别疼痛良好恢复的阳性预测值(PPV)为0.85(95%CI,0.82-0.88)。
- 简单截断值识别睡眠良好恢复的PPV为0.63(95%CI,0.59-0.67)。
- 简单截断值识别焦虑良好恢复的PPV为0.76(95%CI,0.72-0.80)。
临床怎么用
- 腕戴设备生物标志物可能作为高风险人群创伤暴露后疼痛、睡眠和焦虑症状结局的筛查工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adverse posttraumatic neuropsychiatric sequelae after traumatic stress exposure are common and have higher incidence among socioeconomically disadvantaged populations. Pain, depression, avoidance of trauma reminders, reexperiencing trauma, anxiety, hyperarousal, sleep disruption, and nightmares have been reported. Wrist-wearable devices with accelerometers capable of assessing 24-hour rest-activity characteristics are prevalent and may have utility in measuring these outcomes. OBJECTIVE: To evaluate whether wrist-wearable devices can provide useful biomarkers for recovery after traumatic stress exposure. DESIGN, SETTING, AND PARTICIPANTS: Data were analyzed from a diverse cohort of individuals seen in the emergency department after experiencing a traumatic stress exposure, as part of the Advancing Understanding of Recovery After Trauma (AURORA) study. Participants recruited from 27 emergency departments wore wrist-wearable devices for 8 weeks, beginning in the emergency department, and completed serial assessments of neuropsychiatric symptoms. A total of 19 019 patients were screened. Of these, 3040 patients met study criteria, provided informed consent, and completed baseline assessments. A total of 2021 provided data from wrist-wearable devices, completed the 8-week assessment, and were included in this analysis. The data were randomly divided into 2 equal parts (n = 1010) for biomarker identification and validation. Data were collected from September 2017 to January 2020, and data were analyzed from May 2020 to November 2022. EXPOSURES: Participants were recruited for the study after experiencing a traumatic stress exposure (most commonly motor vehicle collision). MAIN OUTCOMES AND MEASURES: Rest-activity characteristics were derived and validated from wrist-wearable devices associated with specific self-reported symptom domains at a point in time and changes in symptom severity over time. RESULTS: Of 2021 included patients, 1257 (62.2%) were female, and the mean (SD) age was 35.8 (13.0) years. Eight wrist-wearable device biomarkers for symptoms of adverse posttraumatic neuropsychiatric sequelae exceeded significance thresholds in the derivation cohort. One of these, reduced 24-hour activity variance, was associated with greater pain severity (r = -0.14; 95% CI, -0.20 to -0.07). Changes in 6 rest-activity measures were associated with changes in pain over time, and changes in the number of transitions between sleep and wake over time were associated with changes in pain, sleep, and anxiety. Simple cutoffs for these biomarkers identified individuals with good recovery for pain (positive predictive value [PPV], 0.85; 95% CI, 0.82-0.88), sleep (PPV, 0.63; 95% CI, 0.59-0.67, and anxiety (PPV, 0.76; 95% CI, 0.72-0.80) with high predictive value. CONCLUSIONS AND RELEVANCE: These findings suggest that wrist-wearable device biomarkers may have utility as screening tools for pain, sleep, and anxiety symptom outcomes after trauma exposure in high-risk populations.
引用
- Straus LD, An X, Ji Y, et al. Utility of Wrist-Wearable Data for Assessing Pain, Sleep, and Anxiety Outcomes After Traumatic Stress Exposure. JAMA Psychiatry. 2023. PMID: 36630119. doi:10.1001/jamapsychiatry.2022.4533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。